Structure of the RNA-dependent RNA polymerase P2 from the cystovirus φ8 by Latimer-Smith, M, Salgado, PS, Forsyth, I, Makeyev, E, Poranen, MM, Stuart, DI, Grimes, JM, El Omari, K

Assembly intermediates of orthoreovirus captured in the cell by Sutton, G, Sun, D, Fu, X, Kotecha, A, Hecksel, CW, Clare, DK, Zhang, P, Stuart, DI, Boyce, M

The impact of exchanging the light and heavy chains on the structures of bovine ultralong antibodies by Clarke, JD, Douangamath, A, Mikolajek, H, Bonnet-Di Placido, M, Ren, J, Fry, EE, Stuart, DI, Hammond, JA, Owens, RJ

Where is crystallography going? by Grimes, JM, Hall, DR, Ashton, AW, Evans, G, Owen, RL, Wagner, A, Mcauley, KE, von Delft, F, Orville, AM, Sorensen, T, Walsh, MA, Ginn, HM, Stuart, DI

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum by Dejnirattisai, W, Shaw, RH, Supasa, P, Liu, C, Stuart, AS, Pollard, AJ, Liu, X, Lambe, T, Crook, D, Stuart, DI, Mongkolsapaya, J, Nguyen-Van-Tam, JS, Snape, MD, Screaton, GR

Cooperativity and induced oligomerization control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies by Asor, R, Olerinyova, A, Burnap, SA, Kushwah, MS, Hensen, M, Vasiljevic, S, Chang, L, Dejnirattisa, W, Supasa, P, Stuart, DI, Screaton, GR, Zitzmann, N, Benesch, JLP, Struwe, WB, Kukura, P

3D correlative cryo-structured illumination fluorescence and soft x-ray microscopy elucidates reovirus intracellular release pathway by Kounatidis, I, Stanifer, ML, Phillips, MA, Paul-Gilloteaux, P, Heiligenstein, X, Wang, H, Okolo, CA, Fish, TM, Spink, MC, Stuart, DI, Davis, I, Boulant, S, Grimes, JM, Dobbie, IM, Harkiolaki, M

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy by Zeltins, A, West, J, Zabel, F, El-Turabi, A, Balke, I, Haas, S, Maudrich, M, Storni, F, Engernoff, P, Jennings, GT, Jennings, GT, Kotecha, A, Stuart, DI, Foerster, J, Bachmann, M

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK by Wei, J, Matthews, P, Stoesser, N, Newton, JN, Diamond, I, Studley, R, Taylor, N, Bell, JI, Farrar, J, Kolenchery, J, Marsden, B, Hoosdally, S, Jones, EY, Stuart, DI, Crook, D, Peto, TEA, Walker, AS, Pouwels, K, Eyre, D

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections by Eyre, DW, Lumley, SF, O'Donnell, D, Stoesser, NE, Matthews, PC, Howarth, A, Hatch, SB, Marsden, BD, Cox, S, James, T, Cornall, RJ, Stuart, DI, Screaton, G, Ebner, D, Crook, DW, Conlon, CP, Jeffery, K, Walker, TM, Peto, TEA

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population by Wei, J, Matthews, PC, Stoesser, N, Maddox, T, Lorenzi, L, Studley, R, Bell, JI, Newton, JN, Farrar, J, Diamond, I, Rourke, E, Howarth, A, Marsden, BD, Hoosdally, S, Jones, EY, Stuart, DI, Crook, DW, Peto, TEA, Pouwels, KB, Walker, AS, Eyre, DW

Accelerating drug target inhibitor discovery with a deep generative foundation model by Chenthamarakshan, V, Hoffman, SC, Owen, CD, Lukacik, P, Strain-Damerell, C, Fearon, D, Malla, TR, Tumber, A, Schofield, CJ, Duyvesteyn, HME, Dejnirattisai, W, Carrique, L, Walter, TS, Screaton, GR, Matviiuk, T, Mojsilovic, A, Crain, J, Walsh, MA, Stuart, DI, Das, P

Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines by Sherry, L, Bahar, MW, Porta, C, Fox, H, Grehan, K, Nasta, V, Duyvesteyn, HME, De Colibus, L, Marsian, J, Murdoch, I, Ponndorf, D, Kim, S, Shah, S, Carlyle, S, Swanson, JJ, Matthews, S, Nicol, C, Lomonossoff, GP, Macadam, AJ, Fry, EE, Stuart, DI, Stonehouse, NJ, Rowlands, DJ

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status by Eyre, DW, Lumley, SF, Wei, J, Cox, S, James, T, Justice, A, Jesuthasan, G, O'Donnell, D, Howarth, A, Hatch, SB, Marsden, BD, Jones, EY, Stuart, DI, Ebner, D, Hoosdally, S, Crook, DW, Peto, TEA, Walker, TM, Stoesser, NE, Matthews, PC, Pouwels, KB, Walker, AS, Jeffery, K

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy by Ragonnet-Cronin, M, Nutalai, R, Huo, J, Dijokaite-Guraliuc, A, Das, R, Tuekprakhon, A, Supasa, P, Liu, C, Selvaraj, M, Groves, N, Hartman, H, Ellaby, N, Mark Sutton, J, Bahar, MW, Zhou, D, Fry, E, Ren, J, Brown, C, Klenerman, P, Dunachie, SJ, Mongkolsapaya, J, Hopkins, S, Chand, M, Stuart, DI, Screaton, GR, Rokadiya, S

Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19 by Redhead, MA, Owen, CD, Brewitz, L, Collette, AH, Lukacik, P, Strain-Damerell, C, Robinson, SW, Collins, PM, Schäfer, P, Swindells, M, Radoux, CJ, Hopkins, IN, Fearon, D, Douangamath, A, von Delft, F, Malla, TR, Vangeel, L, Vercruysse, T, Thibaut, J, Leyssen, P, Nguyen, T-T, Hull, M, Tumber, A, Hallett, DJ, Schofield, CJ, Stuart, DI, Hopkins, AL, Walsh, MA

Antibody status and incidence of SARS-CoV-2 infection in health care workers by Lumley, SF, O'Donnell, D, Stoesser, NE, Matthews, PC, Howarth, A, Hatch, SB, Marsden, BD, Cox, S, James, T, Warren, F, Peck, LJ, Ritter, TG, de Toledo, Z, Warren, L, Axten, D, Cornall, RJ, Jones, EY, Stuart, DI, Screaton, G, Ebner, D, Hoosdally, S, Chand, M, Crook, DW, O'Donnell, A-M, Conlon, CP, Pouwels, KB, Walker, AS, Peto, TEA, Hopkins, S, Walker, T, Jeffery, K, Eyre, DW

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants by Liu, C, Zhou, D, Nutalai, R, Duyvesteyn, HME, Tuekprakhon, A, Ginn, HM, Dejnirattisai, W, Supasa, P, Mentzer, AJ, Wang, B, Case, JB, Zhao, Y, Skelly, DT, Chen, RE, Johnson, SA, Ritter, TG, Mason, C, Malik, T, Temperton, N, Paterson, NG, Williams, MA, Hall, DR, Clare, DK, Howe, A, Goulder, PJR, Fry, EE, Diamond, MS, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR

Application of the use of high-throughput technologies to the determination of protein structures of bacterial and viral pathogens by Fogg, MJ, Alzari, P, Bahar, M, Bertini, I, Betton, JM, Burmeister, WP, Cambillau, C, Canard, B, Corrondo, MA, Coll, M, Daenke, S, Dym, O, Egloff, MP, Enguita, FJ, Geerlof, A, Haouz, A, Jones, TA, Ma, Q, Manicka, SN, Migliardi, M, Nordlund, P, Owens, RJ, Peleg, Y, Schneider, G, Schnell, R, Stuart, DI, Tarbouriech, N, Unge, T, Wilkinson, AJ, Wilmanns, M, Wilson, KS, Zimhony, O, Grimes, JM

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 by Huo, J, Le Bas, A, Ruza, RR, Duyvesten, HME, Mikolajek, H, Malinauskas, T, Tan, TK, Rijal, P, Dumoux, M, Ward, PN, Ren, J, Zhou, D, Harrison, PJ, Weckener, M, Clare, DK, Vogirala, VK, Radecke, J, Moynié, L, Zhao, Y, Gilbert-Jaramillo, J, Knight, ML, Tree, JA, Buttigieg, KR, Coombes, N, Elmore, MJ, Carroll, MW, Carrique, L, Shah, PNM, James, W, Townsend, AR, Stuart, DI, Owens, RJ, Naismith, JH